Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6 - PubMed
5 hours ago
- #immunotherapy
- #breast cancer
- #CDK4/6
- Cyclin D-CDK4/6 regulates the CD155-CD226-TIGIT immune axis.
- CDK4/6 inhibition upregulates CD155 in cancer cells and downregulates TIGIT in lymphocytes.
- Effects observed in human breast cancer cell lines, mouse models, and patient biopsies.
- CDK4/6 inhibition may shift balance from immunoinhibitory CD155-TIGIT to immunostimulatory CD155-CD226.
- Combination of CDK4/6 inhibitors and anti-TIGIT antibodies could enhance antitumor immunity.
- Study suggests potential for synergistic antitumor effects with combined therapy.